CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We list the best free presentation software, to make it simple and easy to create professional presentations without a subscription to Microsoft PowerPoint. While PowerPoint is the market leader ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Amanda Smith is a freelance journalist and writer. She reports on culture, society, human interest and technology. Her stories hold a mirror to society, reflecting both its malaise and its beauty.

And in December, it shelved a sickle cell treatment similar to Casgevy, the treatment approved in late 2023 from Vertex and CRISPR Therapeutics. Casgevy’s slow rollout — it appears to have ...

Developed collaboratively by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is designed to treat sickle cell disease and transfusion-dependent beta-thalassemia. The therapy involves editing ...